Back to Stocks

CELZ

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
7 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Creative Medical Technology Holdings is approaching a pivotal inflection point as it transitions from a capital-intensive development phase to a high-value clinical milestone period.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic clinical narrative, the financial reality for Creative Medical Technology Holdings is precarious. The company reported zero revenue for the quarter, while operating losses reached $1.46 million.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CELZ filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company standing at a binary crossroads. On one hand, the regulatory and clinical progress of the CELZ-201-DDT program is impressive, with Fast Track status and completed enrollment providing a clear path toward a potential value-unlocking event. The shift toward a leaner operational structure suggests a management team focused on surviving until the data readout. However, the lack of organic revenue and the rapid erosion of cash reserves create a race against time. The tension between the imminent clinical catalyst and the shrinking financial runway means that the window for a positive outcome is narrow. Investors are essentially weighing the probability of a successful ADAPT trial against the certainty of a fragile balance sheet and the high likelihood of future shareholder dilution.

Selected Quarter

Core Takeaway

The company has reached a binary catalyst point with the ADAPT trial, but its survival depends on a successful readout before cash is exhausted.

Investor Lens

The trade-off is between the high-reward potential of a breakthrough regenerative therapy and the high-risk profile of a pre-revenue micro-cap with dwindling cash.

Watch Next

Top-line data release from the CELZ-201 ADAPT clinical trial and any new financing announcements.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.45Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 8

Company generated zero revenue for the quarter with a net loss of $1.4M.

earnings miss
90%
bearishMay 8

Operating loss represents nearly 100% of total expenses due to zero revenue.

margin compression
80%
bearishMay 8

Over 6 million warrants outstanding pose significant dilution risk for future capital raises.

dilution risk
70%
bullishMay 8

Strategic shift toward capital efficiency with a 27% reduction in R&D spending.

management change
60%
bearishMay 8

Company generated zero revenue for the quarter with a net loss of $1.4M.

earnings miss
90%
bearishMay 8

Operating loss represents nearly 100% of total expenses due to zero revenue.

margin compression
80%
bearishMay 8

Over 6 million warrants outstanding pose significant dilution risk for future capital raises.

dilution risk
70%
bullishMay 8

Strategic shift toward capital efficiency with a 27% reduction in R&D spending.

management change
60%
bearishMay 8

Company generated zero revenue for the quarter with a net loss of $1.4M.

earnings miss
90%
bearishMay 8

Operating loss represents nearly 100% of total expenses due to zero revenue.

margin compression
80%
bearishMay 8

Over 6 million warrants outstanding pose significant dilution risk for future capital raises.

dilution risk
70%
bullishMay 8

Strategic shift toward capital efficiency with a 27% reduction in R&D spending.

management change
60%
bearishMay 8

Company generated zero revenue for the quarter with a net loss of $1.4M.

earnings miss
90%
bearishMay 8

Operating loss represents nearly 100% of total expenses due to zero revenue.

margin compression
80%
bearishMay 8

Over 6 million warrants outstanding pose significant dilution risk for future capital raises.

dilution risk
70%
bullishMay 8

Strategic shift toward capital efficiency with a 27% reduction in R&D spending.

management change
60%
bearishMay 8

Company generated zero revenue for the quarter with a net loss of $1.4M.

earnings miss
90%
bearishMay 8

Operating loss represents nearly 100% of total expenses due to zero revenue.

margin compression
80%
bearishMay 8

Over 6 million warrants outstanding pose significant dilution risk for future capital raises.

dilution risk
70%
bullishMay 8

Strategic shift toward capital efficiency with a 27% reduction in R&D spending.

management change
60%
bearishMay 8

Company generated zero revenue for the quarter with a net loss of $1.4M.

earnings miss
90%
bearishMay 8

Operating loss represents nearly 100% of total expenses due to zero revenue.

margin compression
80%
bearishMay 8

Over 6 million warrants outstanding pose significant dilution risk for future capital raises.

dilution risk
70%
bullishMay 8

Strategic shift toward capital efficiency with a 27% reduction in R&D spending.

management change
60%
bearishMay 8

Company generated zero revenue for the quarter with a net loss of $1.4M.

earnings miss
90%
bearishMay 8

Operating loss represents nearly 100% of total expenses due to zero revenue.

margin compression
80%
bearishMay 8

Over 6 million warrants outstanding pose significant dilution risk for future capital raises.

dilution risk
70%
bullishMay 8

Strategic shift toward capital efficiency with a 27% reduction in R&D spending.

management change
60%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing reveals a company standing at a binary crossroads. On one hand, the regulatory and clinical progress of the CELZ-201-DDT program is impressive, with Fast Track status and completed enrollment providing a clear path toward a potential value-unlocking event. The shift toward a leaner operational structure suggests a management team focused on surviving until the data readout. However, the lack of organic revenue and the rapid erosion of cash reserves create a race against time. The tension between the imminent clinical catalyst and the shrinking financial runway means that the window for a positive outcome is narrow. Investors are essentially weighing the probability of a successful ADAPT trial against the certainty of a fragile balance sheet and the high likelihood of future shareholder dilution.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.